CA2099772A1 - Anti-hiv activity of liposomal nystatin and amphotericin b - Google Patents
Anti-hiv activity of liposomal nystatin and amphotericin bInfo
- Publication number
- CA2099772A1 CA2099772A1 CA002099772A CA2099772A CA2099772A1 CA 2099772 A1 CA2099772 A1 CA 2099772A1 CA 002099772 A CA002099772 A CA 002099772A CA 2099772 A CA2099772 A CA 2099772A CA 2099772 A1 CA2099772 A1 CA 2099772A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- sterol
- weight
- nystatin
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
ANTI-HIV ACTIVITY OF
LIPOSOMAL NYSTATIN AND AMPHOTERICIN B
ABSTRACT OF THE INVENTION
A method is disclosed for inhibiting the replication of HIV-1 virus. The method includes the step of administering to a subject which is infected with HIV-1 a pharmaceutically effective amount of a liposomal composition which comprises at least one lipid and a polyene selected from nystatin and amphotericin B. Such liposomal compositions have been found to be selectively toxic for HIV-infected cells.The composition preferably comprises nystatin, dimyristoyl phosphatidyl choline, and dimyristoyl phosphatidyl glycerol, with the weight ratio of the latter two components being about 7:3.
LIPOSOMAL NYSTATIN AND AMPHOTERICIN B
ABSTRACT OF THE INVENTION
A method is disclosed for inhibiting the replication of HIV-1 virus. The method includes the step of administering to a subject which is infected with HIV-1 a pharmaceutically effective amount of a liposomal composition which comprises at least one lipid and a polyene selected from nystatin and amphotericin B. Such liposomal compositions have been found to be selectively toxic for HIV-infected cells.The composition preferably comprises nystatin, dimyristoyl phosphatidyl choline, and dimyristoyl phosphatidyl glycerol, with the weight ratio of the latter two components being about 7:3.
Description
UTFC:lg ANTI-HIV ACTIVITY OF
LIPOSOMAL NYSTATIN AND AMPHOTERICIN B
The United States may own certain rights in this invention as the development of part of the present invention was supported by grant number NIH-NOl-AI-72639 from the National Institutes of Health, Department of Health and Human Services.
This application is a continuation in part of U.S.
application serial number 314,710, filed on February 23, 1989. That application is incorporated here by reference.
Acquired immunodeficiency syndrome (AIDS), resulting from infection by the human immunodeficiency virus (HIV), affects thousands of people around the world, and is uniformly fatal. Extensive research efforts are underway in an attempt to develop methods of curing or preventing this disease, but as of the present, no completely satisfactory solution has been found.
One group of drugs with known antibiotic properties is the polyene macrolides, which are secondary metabolites produced by various species of Streptomyces. Without being bound by any particular theory of activity, the previously-known antibiotic properties of the polyenes appears to be based on their interaction with sterols in the cell membranes of infectious agents, such as fungal cell membranes. As a result of this interaction, the 2 ~ 2 membranes are rendered selectively permeable to the outflow of vital constituents, such as potassium.
Nystatin and amphotericin B are two specific examples of polyenes. Although they have previously demonstrated some antibiotic activity, they have not been previously demonstrated to have a practical use with respect to treatment or prophylaxis of AIDS. The present invention is based on the surprising discovery that certain formulations comprising nystatin or amphotericn B do in fact have practical and useful activity against HIV-1 virus.
The present invention, in one aspect, concerns a method for inhibiting the replication of HIV-1 virus, comprising the step of administering to a subject which is infected with HIV-l a pharmaceutically effective amount of a liposomal composition which comprises a polyene selected from nystatin and amphotericin B. The composition will comprise liposomal vesicles, formed of at least one phospholipid, in which a polyene selected from nystatin and amphotericin B is entrapped or ~ncapsulated. The composition can optionally also comprise a sterol, such as cholesterol.
In another aspect, the pr~sent invention relates to a pharmaceutical composition comprising a cytotoxicity-exclusionary amount of a liposomal polyene selected from nystatin and amphotericin B. In this respect, the invention is based on the therapeutic window created by the selective activity of liposomal nystatin and amphotericin B, whereby a dose of such compositions that is toxic to HIV-infected cells is not substantially toxic to uninfected cells. "Cytotoxicity-exclusionary" means a composition or dosage which has an LD50 for HIV-infected target cells above the IDso for noninfected target cells.
` - 2~7~
In another aspect, the present invention concerns a method of inhibiting the replication of HIV-l virus, comprising the step of administering to a subject which is infected with HIV-l a vector-interdicting amount of a composition which comprises liposomal vesicles in which a polyene selected from nystatin and amphotericin B is incorporated. A "vector-interdicting amount" refers to the amount which will result in the inhibition, blocking, or elimination of a vector pathway for HIV proliferation and/or transmission in the treatment of an animal.
"Vector pathway" refers to organ and organelle (i.e., nonfluid) replication-based pathways of HIV proliferation and transmission.
In preferred embodiments of the invention, the lipids will make up between about 25% and about 90% by weight of the total amount oP lipid and nystatin. If a sterol is included, it will preferably make up between about 10% and about 75% by weight, most preferably between about 30~ and about 60%, of the total amount of nystatin, lipid, and sterol. In an especially preferred embodiment, the composition consists essentially of nystatin, dimyri_coyl phosphatidyl choline, and dimyristoyl phosphatidyl glycerol, with the weight ratio of DMPC:DMPG being about 7:3. The weight ratio of nystatin to lipids is preferably about 1:10.
The present invention permits the selectively toxic treatment of an animal that is infected with HIV-1 virus, whereby infected cells are selectively killed, while avoiding substantial toxicity to other cells. The present invention takes advantage of the surprising ability of liposomal nystatin and amphotericin B to inhibit the replication and/or transmission of HIV-1. This activity is especially surprising in view of the lack of such activity on the part of liposomal formulations of other polyenes, such as mepartricin and hamycin. The compositions and methods of the present invention should be useful for the treatment and/or prophylaxis of AIDS in animals, including humans.
In the method of the present invention, the agent to be administered comprises a polyene selected from the group consisting of nystatin and amphotericin B, at least one phospholipid, and optionally a sterol, such as cholesterol. The phospholipid takes the form of lipid vesicles or liposomes, in which ~he polyene is entrapped or encapsulated. (For the sake of simplicity, in this patent all lipid -~esicles in which polyene is entrapped or encapsulated will be referred to as "liposomes".) The liposomes can be unilamellar, multilamellar, or can have an undefined lamellar construction.
The phospholipids are preferably selected from the group consisting of phosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, sphingomyelin, and phosphatidic acid. The most preferred phospholipids are dimyristoy~ phosphatidyl choline and dimyristoyl phosphatidyl glycerol. However, other lipids can be used.
When the liposomes comprise dimyristoyl phosphatidyl choline and dimyristoyl phosphatidyl glycerol, those two lipids are preferably present in a weight ratio of between 1:10 and 10:1, with the most preferred ratio being 7:3 DMPC: DMPG. The lipids preferably comprise from about 25%
to about 90 % by weight o~ the overall composition of lipid, nystatin, and optionally, sterol.
It is useful to include sterol in the composition in order to reduce the toxicity that is typically associated with free nystatin. The sterol, for example cholesterol, can be included in an amount equal to from 10% to 75% by 2 ~ 9~7 i~!2 weiyht of the overall composition (on a dry basis). A
more preferred range is 30% to 60%.
The mode of administration is preferably parenteral, i.e., by intravenous, intraarterial, intramu~cular, intralymphatic, intraperitoneal, subcutaneous, intrapleural, or intrathecal injection or infusion. The administration could also be through inhalation or topical or oral means. The composition can be employed in admixture with conventional excipients, i.e~, pharmaceutically acceptable carrier substances which do not deleteriously react with the active compositions. The composition is preferably formulated as a pharmaceutically acceptable solution, such as a sterile isotonic aqueous solution. A pharmaceutically effective amount will be administered, preferably in a dosage between about 0.1 mg of nystatinlkg of body weight and about 80 mg/kg. ~he presently preferred dosage is about 4 mg/kg, administered three times a week for about six months.
Further details regarding the making and use of the present invention can be determined from the following examples.
Examples Druas. Nystatin (Nys) was obtained from American Cyanamid Company. Liposomal nystatin (L-Nys) was prepared as previously described. Briefly, the drug in methanol and the phospholipids, dimyristoyl phosphatidyl choline (DMPC) and dimyristoyl phosphatidyl glycerol (DMPG) dissolved in chloroform (DMPC:DMPG, 7:3 by weight) were mixed in a ratio of 1:10 (nys:phospholipid) and the organic solvents were evaporated. The dried lipid film was dispersed with o.9% NaCl solution.
2~977i' Another procedure for preparing the composition is as follows. 7 g of DMPC (Lipoid KG, Ludwigshafen, West Germany) and 3 g of DMPG (Lipoid KG~ are mixed with 250 cc of t-butyl alcohol tFisher Scienti~ic, Fairlawn, New Jersey). 250 cc of water are added and mixed until dissolved. This solution is then passed through a 0.45 ~M
pore size filter cartridge. Separately, 1.1 g Nys is dissolved in 7 cc of methyl sulfoxide (Fisher Scientific~, and mixed until dissolved. The nys solution is then passed through a 0.45 ~M pore size filter cartridge, and the lipid solution and nys solution are then mixed. The concentration is adjusted to 1.1 mg/ml by adding an appropriate volume of diluent, and the solution is then passed through a sterile, 0.22 ~M membrane. The solvents can be removed by lyophilization, and the resulting preliposomal powder can be reconstituted whe~ desired by adding water or saline solution.
Virus. HIV-l (HTLV-III/B) was prepared from HIV infected H9 cells in culture. Cells were harvested and the virus isolated from the culture medium by banding on sucrose gradients. The virus band sediment had a density of 1.16 to 1.19 g/ml, and was collected by pelleting. The pellet was resuspended in TNE (lOmM Tris. HCl, pH 7.5, 0.lM NaCl, 0.001 EDTA) at 2xlOIl virus particles/ml.
H9 Cells. H9 cells are a transformed line of human lymphocytes permissive for HIV-l. The cultures were maintained using RPMI supplemented with 20% fetal bovine serum, 2% glutamine and 1% gentamicin. Cells were harvested in log phase of growth for testing and seeded at 5x105 cells/test culture.
Culture Conditions. HIV-l at 5X108 particles/ml was added to the test cultures (5x105 cells/ml) simultaneously with compounds to be tested. The cultures were incubated for 4 - 2~9772 days at 37 C in an atmosphere containing 5% C02. Cells were then harvested and assayed for virus growth as described below.
~mmunofluorescer.ce Assays. The cells were collected by centrifugation, washed and resuspended in O.OlM phosphate buffered saline (PBS), to approximately lx106 cells/ml.
An aliquot was used for determining cell viability by the exclusion of trypan blue dye. The remaining cells were added to wells on a toxoplasmosis slide, allowed to dry for one hour and fixed in acetone methanol (1:1, v/v) for 15 minutes, as described. After fixation, the slides were pretreated with 10% normal goat serum at room temperature for 30 minutes. The slides were rinsed four times with PBS, 15 minutes each wash. Mouse monoclonal antibody to HIV-1 p24 antigen was added to each slide and incubated for 30 minutes at 37C, in a humidified chamber. The cells were then rinsed with PBS, and washed 4 times as above. The cells were then stained with FITC labeled goat anti-mouse IgG by incubating for 30 minutes as above.
The slides were rinsed with P8S, washed 4 times and given a final wash overnight with fresh PBS. The slides were counterstained with 0.02% Evans blue for 1 minute followed by rinsing with distilled water. After air-drying the slides were mounted with 50% glycerol, and fluorescence measurements were done with a Zeiss fluorescence microscope. The results are expressed as the percent of fluorescent positive cells derived from the average of several microscopic fields.
Reverse TranscriPtase Activity. The supernatant fractions of the test cultures were assayed for reverse transcriptase activity as described previously (Sarin, 1985, 1986). This was measured by the incorporation of 2~ 7 h 3H-deoxythymidine triphosphate into trichloracetic acid-insoluble DNA using (dT)~5:(A)n, as a template primer.
Antibody Induction Assay. C57BL/6 mice were primed with 5 lx107 sheep red blood cells (SRBC's) ip 10 days prior to the experiment. The mice were sacrificed, spleens removed and a homogeneous cell population prepared as using a tissue homogenizer. Cultures were set up with lx107 primed spleen cells, lx105 SRBC's and 0.1 ml of the test compound. The cultures were incubated for 6 days in Click's medium (Click, 1972) under the same conditions as the H9 cultures. After incubation, the supernatant fluids were collected by centrifugation and assayed for the presence oP antibody to sheep red blood cells by the complement dependent immune hemolysis assay.
Complement Dependent Immune Hemolysis. Various dilutions tl:10, l:100, 1:1000) of the culture supernatants were added to lx108 SRBC's for 30 minutes at room te~perature.
~0 The cells were collected by centrifugation, washed with vernal buffer, and mixed with an excess of complement (Gibco) determined by hemolysin titration. The suspensions were incubated for 1 hour in a 37 C water bath. After incubation the supernatants were collected by centrifugation and read spectrophotometrically at 541 nm fo~ the presence of hemoglobin from the lysed SRBC's.
This direct test measures the amount of IgM in the cultures. To measure IgG, total antibody was measured by an indirect technique using rabbit anti-mouse IgG. The antibody was added to the suspensions before the addition of complement to facilitate complement binding. The value obtained from the indirect technique is subtracted from the total antibody and the result is the amount of IgG in the culture. The unit of antibody is defined as the amount of antibody which can sensitize 50% of the SRBC's lysed in the presence of complement.
2~7'72 g Table 1. Anti-HlV-1(111C) activity of liposomal-nystatin Drug Drug Combination H9 cells Percent inhibition of HIV expression ~g/ml tlOu/ml) p17 p24 RT
H9 cells (no virus) 2.52 H9 cells infected 1.72 1 5 Expæri~ent 1 Empty liposomes 0.01 0 0 0.1 1.0 0 0 0 2 0 10.0 0 100.0 0 Liposr~nal- 0.01 2.36 0 0 26 Nystatin 0.1 2.72 35 33 27 2 5 1.0 1.76 50 40 30 10.0 1.6 90 93 70 100.0 ToxicToxic to cells Experincnt 2 Empty liposomes 0.01 0 0.1 1.0 0 0 0 10.0 3 5 100.0 0 0 0 Liposomal- 0.01 0 0 Nystatin 0.1 39 31 44 1.0 54 37 35 4 0 10.0 92 99 78 100.0 Toxic to cells 2~772 Table 2. Anti-HlV-l,~ activity of liposomal-nystaein Drug Drug Combination Percent inhibition of HIV e~lpression Syncytia I~g/mlinhibitionp17 PZ4 RT
Experi lent 1 Empty liposomes 7.5 0 0 0 0 ZO O O O O
Liposomal- 7.5 0 Z9 57 52 Nystatin 10 60 55 83 69 88 81 90 n 2 5 E~periment 2 Empty liposomes 7.5 0 0 0 0 lo o o o n ZO o o o o Liposomal- 7.518 39 60 SZ
~Iystatin 10 58 61 77 62 -2~7~
Anti-HIV ~IIIB) activity of L-Nys in H9 cells In the first set of experiments, in which the effects of L-Nys on HIV (IIIB) infected H9 cells was tested~ the viral antigens pl7 and p24 were inhibited in a dose dependent fashion by L~Nys (see Table 1). RT activity was also inhibited to a general degree. Empty liposomes had no effect on any of the parameters studied. L-Nys was not toxic to uninfected H9 cells at concentrations up to 10 ~gtml; however, at concentrations between 10.0-100.00, L-Nys was toxic to HIV infected cells. HIV-expression was inhibited by L-Nys at concentrations which are not toxic to uninfected H9 cells.
Anti-llIV-lcr activity of L-Nys in Molt-3 cells When the effects of L-Nys on HIV-1cc infected Molt-3 cells was tested, similar to H9 cells, a dose response effect on pl7, p24 and RT was observed (see Table 2).
Furthermore, syncytia formation was also inhibited. Empty liposomes did not have an effect on the parameters studied. L-Nys was not toxic to non-infected Molt-3 cells at the concentrations studied.
The results obtained indicate that L-Nys displayed a selective toxicity for HIV infected cells. L-Nys had direct anti-HIV activity as reflected in the inhibition of syncitia formation, and on HIV infected cells. L-Nys was not toxic even at the higher concentrations used on non-infected cells. The HIV inhibition observed was dose dependent for all parameters tested.
The increased cholesterol observed in HIV-infected cells may make the infected cells more vulnerable to the membrane effects of Nys. We have previously shown that L-Nys was far less toxic to human red blood cells than free Nys, thus liposomal incorporation prevented the direct toxic effects of Nys to mammalian cells. See U.S. patent 2 ~ ,9 9 ~
4,812,312, which is incorporated here by reference. Such was also the case for non-infected l,vmphocytes.
* * *
The preceding description is intended to illustrate specific embodiments of the present invention. It i5 not intended to be an exhaustive list of all possible embodiments. Person skilled in this field will recognize that modifications could be made to the compositions and methods described above that would remain within the scope of the present invention.
LIPOSOMAL NYSTATIN AND AMPHOTERICIN B
The United States may own certain rights in this invention as the development of part of the present invention was supported by grant number NIH-NOl-AI-72639 from the National Institutes of Health, Department of Health and Human Services.
This application is a continuation in part of U.S.
application serial number 314,710, filed on February 23, 1989. That application is incorporated here by reference.
Acquired immunodeficiency syndrome (AIDS), resulting from infection by the human immunodeficiency virus (HIV), affects thousands of people around the world, and is uniformly fatal. Extensive research efforts are underway in an attempt to develop methods of curing or preventing this disease, but as of the present, no completely satisfactory solution has been found.
One group of drugs with known antibiotic properties is the polyene macrolides, which are secondary metabolites produced by various species of Streptomyces. Without being bound by any particular theory of activity, the previously-known antibiotic properties of the polyenes appears to be based on their interaction with sterols in the cell membranes of infectious agents, such as fungal cell membranes. As a result of this interaction, the 2 ~ 2 membranes are rendered selectively permeable to the outflow of vital constituents, such as potassium.
Nystatin and amphotericin B are two specific examples of polyenes. Although they have previously demonstrated some antibiotic activity, they have not been previously demonstrated to have a practical use with respect to treatment or prophylaxis of AIDS. The present invention is based on the surprising discovery that certain formulations comprising nystatin or amphotericn B do in fact have practical and useful activity against HIV-1 virus.
The present invention, in one aspect, concerns a method for inhibiting the replication of HIV-1 virus, comprising the step of administering to a subject which is infected with HIV-l a pharmaceutically effective amount of a liposomal composition which comprises a polyene selected from nystatin and amphotericin B. The composition will comprise liposomal vesicles, formed of at least one phospholipid, in which a polyene selected from nystatin and amphotericin B is entrapped or ~ncapsulated. The composition can optionally also comprise a sterol, such as cholesterol.
In another aspect, the pr~sent invention relates to a pharmaceutical composition comprising a cytotoxicity-exclusionary amount of a liposomal polyene selected from nystatin and amphotericin B. In this respect, the invention is based on the therapeutic window created by the selective activity of liposomal nystatin and amphotericin B, whereby a dose of such compositions that is toxic to HIV-infected cells is not substantially toxic to uninfected cells. "Cytotoxicity-exclusionary" means a composition or dosage which has an LD50 for HIV-infected target cells above the IDso for noninfected target cells.
` - 2~7~
In another aspect, the present invention concerns a method of inhibiting the replication of HIV-l virus, comprising the step of administering to a subject which is infected with HIV-l a vector-interdicting amount of a composition which comprises liposomal vesicles in which a polyene selected from nystatin and amphotericin B is incorporated. A "vector-interdicting amount" refers to the amount which will result in the inhibition, blocking, or elimination of a vector pathway for HIV proliferation and/or transmission in the treatment of an animal.
"Vector pathway" refers to organ and organelle (i.e., nonfluid) replication-based pathways of HIV proliferation and transmission.
In preferred embodiments of the invention, the lipids will make up between about 25% and about 90% by weight of the total amount oP lipid and nystatin. If a sterol is included, it will preferably make up between about 10% and about 75% by weight, most preferably between about 30~ and about 60%, of the total amount of nystatin, lipid, and sterol. In an especially preferred embodiment, the composition consists essentially of nystatin, dimyri_coyl phosphatidyl choline, and dimyristoyl phosphatidyl glycerol, with the weight ratio of DMPC:DMPG being about 7:3. The weight ratio of nystatin to lipids is preferably about 1:10.
The present invention permits the selectively toxic treatment of an animal that is infected with HIV-1 virus, whereby infected cells are selectively killed, while avoiding substantial toxicity to other cells. The present invention takes advantage of the surprising ability of liposomal nystatin and amphotericin B to inhibit the replication and/or transmission of HIV-1. This activity is especially surprising in view of the lack of such activity on the part of liposomal formulations of other polyenes, such as mepartricin and hamycin. The compositions and methods of the present invention should be useful for the treatment and/or prophylaxis of AIDS in animals, including humans.
In the method of the present invention, the agent to be administered comprises a polyene selected from the group consisting of nystatin and amphotericin B, at least one phospholipid, and optionally a sterol, such as cholesterol. The phospholipid takes the form of lipid vesicles or liposomes, in which ~he polyene is entrapped or encapsulated. (For the sake of simplicity, in this patent all lipid -~esicles in which polyene is entrapped or encapsulated will be referred to as "liposomes".) The liposomes can be unilamellar, multilamellar, or can have an undefined lamellar construction.
The phospholipids are preferably selected from the group consisting of phosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, sphingomyelin, and phosphatidic acid. The most preferred phospholipids are dimyristoy~ phosphatidyl choline and dimyristoyl phosphatidyl glycerol. However, other lipids can be used.
When the liposomes comprise dimyristoyl phosphatidyl choline and dimyristoyl phosphatidyl glycerol, those two lipids are preferably present in a weight ratio of between 1:10 and 10:1, with the most preferred ratio being 7:3 DMPC: DMPG. The lipids preferably comprise from about 25%
to about 90 % by weight o~ the overall composition of lipid, nystatin, and optionally, sterol.
It is useful to include sterol in the composition in order to reduce the toxicity that is typically associated with free nystatin. The sterol, for example cholesterol, can be included in an amount equal to from 10% to 75% by 2 ~ 9~7 i~!2 weiyht of the overall composition (on a dry basis). A
more preferred range is 30% to 60%.
The mode of administration is preferably parenteral, i.e., by intravenous, intraarterial, intramu~cular, intralymphatic, intraperitoneal, subcutaneous, intrapleural, or intrathecal injection or infusion. The administration could also be through inhalation or topical or oral means. The composition can be employed in admixture with conventional excipients, i.e~, pharmaceutically acceptable carrier substances which do not deleteriously react with the active compositions. The composition is preferably formulated as a pharmaceutically acceptable solution, such as a sterile isotonic aqueous solution. A pharmaceutically effective amount will be administered, preferably in a dosage between about 0.1 mg of nystatinlkg of body weight and about 80 mg/kg. ~he presently preferred dosage is about 4 mg/kg, administered three times a week for about six months.
Further details regarding the making and use of the present invention can be determined from the following examples.
Examples Druas. Nystatin (Nys) was obtained from American Cyanamid Company. Liposomal nystatin (L-Nys) was prepared as previously described. Briefly, the drug in methanol and the phospholipids, dimyristoyl phosphatidyl choline (DMPC) and dimyristoyl phosphatidyl glycerol (DMPG) dissolved in chloroform (DMPC:DMPG, 7:3 by weight) were mixed in a ratio of 1:10 (nys:phospholipid) and the organic solvents were evaporated. The dried lipid film was dispersed with o.9% NaCl solution.
2~977i' Another procedure for preparing the composition is as follows. 7 g of DMPC (Lipoid KG, Ludwigshafen, West Germany) and 3 g of DMPG (Lipoid KG~ are mixed with 250 cc of t-butyl alcohol tFisher Scienti~ic, Fairlawn, New Jersey). 250 cc of water are added and mixed until dissolved. This solution is then passed through a 0.45 ~M
pore size filter cartridge. Separately, 1.1 g Nys is dissolved in 7 cc of methyl sulfoxide (Fisher Scientific~, and mixed until dissolved. The nys solution is then passed through a 0.45 ~M pore size filter cartridge, and the lipid solution and nys solution are then mixed. The concentration is adjusted to 1.1 mg/ml by adding an appropriate volume of diluent, and the solution is then passed through a sterile, 0.22 ~M membrane. The solvents can be removed by lyophilization, and the resulting preliposomal powder can be reconstituted whe~ desired by adding water or saline solution.
Virus. HIV-l (HTLV-III/B) was prepared from HIV infected H9 cells in culture. Cells were harvested and the virus isolated from the culture medium by banding on sucrose gradients. The virus band sediment had a density of 1.16 to 1.19 g/ml, and was collected by pelleting. The pellet was resuspended in TNE (lOmM Tris. HCl, pH 7.5, 0.lM NaCl, 0.001 EDTA) at 2xlOIl virus particles/ml.
H9 Cells. H9 cells are a transformed line of human lymphocytes permissive for HIV-l. The cultures were maintained using RPMI supplemented with 20% fetal bovine serum, 2% glutamine and 1% gentamicin. Cells were harvested in log phase of growth for testing and seeded at 5x105 cells/test culture.
Culture Conditions. HIV-l at 5X108 particles/ml was added to the test cultures (5x105 cells/ml) simultaneously with compounds to be tested. The cultures were incubated for 4 - 2~9772 days at 37 C in an atmosphere containing 5% C02. Cells were then harvested and assayed for virus growth as described below.
~mmunofluorescer.ce Assays. The cells were collected by centrifugation, washed and resuspended in O.OlM phosphate buffered saline (PBS), to approximately lx106 cells/ml.
An aliquot was used for determining cell viability by the exclusion of trypan blue dye. The remaining cells were added to wells on a toxoplasmosis slide, allowed to dry for one hour and fixed in acetone methanol (1:1, v/v) for 15 minutes, as described. After fixation, the slides were pretreated with 10% normal goat serum at room temperature for 30 minutes. The slides were rinsed four times with PBS, 15 minutes each wash. Mouse monoclonal antibody to HIV-1 p24 antigen was added to each slide and incubated for 30 minutes at 37C, in a humidified chamber. The cells were then rinsed with PBS, and washed 4 times as above. The cells were then stained with FITC labeled goat anti-mouse IgG by incubating for 30 minutes as above.
The slides were rinsed with P8S, washed 4 times and given a final wash overnight with fresh PBS. The slides were counterstained with 0.02% Evans blue for 1 minute followed by rinsing with distilled water. After air-drying the slides were mounted with 50% glycerol, and fluorescence measurements were done with a Zeiss fluorescence microscope. The results are expressed as the percent of fluorescent positive cells derived from the average of several microscopic fields.
Reverse TranscriPtase Activity. The supernatant fractions of the test cultures were assayed for reverse transcriptase activity as described previously (Sarin, 1985, 1986). This was measured by the incorporation of 2~ 7 h 3H-deoxythymidine triphosphate into trichloracetic acid-insoluble DNA using (dT)~5:(A)n, as a template primer.
Antibody Induction Assay. C57BL/6 mice were primed with 5 lx107 sheep red blood cells (SRBC's) ip 10 days prior to the experiment. The mice were sacrificed, spleens removed and a homogeneous cell population prepared as using a tissue homogenizer. Cultures were set up with lx107 primed spleen cells, lx105 SRBC's and 0.1 ml of the test compound. The cultures were incubated for 6 days in Click's medium (Click, 1972) under the same conditions as the H9 cultures. After incubation, the supernatant fluids were collected by centrifugation and assayed for the presence oP antibody to sheep red blood cells by the complement dependent immune hemolysis assay.
Complement Dependent Immune Hemolysis. Various dilutions tl:10, l:100, 1:1000) of the culture supernatants were added to lx108 SRBC's for 30 minutes at room te~perature.
~0 The cells were collected by centrifugation, washed with vernal buffer, and mixed with an excess of complement (Gibco) determined by hemolysin titration. The suspensions were incubated for 1 hour in a 37 C water bath. After incubation the supernatants were collected by centrifugation and read spectrophotometrically at 541 nm fo~ the presence of hemoglobin from the lysed SRBC's.
This direct test measures the amount of IgM in the cultures. To measure IgG, total antibody was measured by an indirect technique using rabbit anti-mouse IgG. The antibody was added to the suspensions before the addition of complement to facilitate complement binding. The value obtained from the indirect technique is subtracted from the total antibody and the result is the amount of IgG in the culture. The unit of antibody is defined as the amount of antibody which can sensitize 50% of the SRBC's lysed in the presence of complement.
2~7'72 g Table 1. Anti-HlV-1(111C) activity of liposomal-nystatin Drug Drug Combination H9 cells Percent inhibition of HIV expression ~g/ml tlOu/ml) p17 p24 RT
H9 cells (no virus) 2.52 H9 cells infected 1.72 1 5 Expæri~ent 1 Empty liposomes 0.01 0 0 0.1 1.0 0 0 0 2 0 10.0 0 100.0 0 Liposr~nal- 0.01 2.36 0 0 26 Nystatin 0.1 2.72 35 33 27 2 5 1.0 1.76 50 40 30 10.0 1.6 90 93 70 100.0 ToxicToxic to cells Experincnt 2 Empty liposomes 0.01 0 0.1 1.0 0 0 0 10.0 3 5 100.0 0 0 0 Liposomal- 0.01 0 0 Nystatin 0.1 39 31 44 1.0 54 37 35 4 0 10.0 92 99 78 100.0 Toxic to cells 2~772 Table 2. Anti-HlV-l,~ activity of liposomal-nystaein Drug Drug Combination Percent inhibition of HIV e~lpression Syncytia I~g/mlinhibitionp17 PZ4 RT
Experi lent 1 Empty liposomes 7.5 0 0 0 0 ZO O O O O
Liposomal- 7.5 0 Z9 57 52 Nystatin 10 60 55 83 69 88 81 90 n 2 5 E~periment 2 Empty liposomes 7.5 0 0 0 0 lo o o o n ZO o o o o Liposomal- 7.518 39 60 SZ
~Iystatin 10 58 61 77 62 -2~7~
Anti-HIV ~IIIB) activity of L-Nys in H9 cells In the first set of experiments, in which the effects of L-Nys on HIV (IIIB) infected H9 cells was tested~ the viral antigens pl7 and p24 were inhibited in a dose dependent fashion by L~Nys (see Table 1). RT activity was also inhibited to a general degree. Empty liposomes had no effect on any of the parameters studied. L-Nys was not toxic to uninfected H9 cells at concentrations up to 10 ~gtml; however, at concentrations between 10.0-100.00, L-Nys was toxic to HIV infected cells. HIV-expression was inhibited by L-Nys at concentrations which are not toxic to uninfected H9 cells.
Anti-llIV-lcr activity of L-Nys in Molt-3 cells When the effects of L-Nys on HIV-1cc infected Molt-3 cells was tested, similar to H9 cells, a dose response effect on pl7, p24 and RT was observed (see Table 2).
Furthermore, syncytia formation was also inhibited. Empty liposomes did not have an effect on the parameters studied. L-Nys was not toxic to non-infected Molt-3 cells at the concentrations studied.
The results obtained indicate that L-Nys displayed a selective toxicity for HIV infected cells. L-Nys had direct anti-HIV activity as reflected in the inhibition of syncitia formation, and on HIV infected cells. L-Nys was not toxic even at the higher concentrations used on non-infected cells. The HIV inhibition observed was dose dependent for all parameters tested.
The increased cholesterol observed in HIV-infected cells may make the infected cells more vulnerable to the membrane effects of Nys. We have previously shown that L-Nys was far less toxic to human red blood cells than free Nys, thus liposomal incorporation prevented the direct toxic effects of Nys to mammalian cells. See U.S. patent 2 ~ ,9 9 ~
4,812,312, which is incorporated here by reference. Such was also the case for non-infected l,vmphocytes.
* * *
The preceding description is intended to illustrate specific embodiments of the present invention. It i5 not intended to be an exhaustive list of all possible embodiments. Person skilled in this field will recognize that modifications could be made to the compositions and methods described above that would remain within the scope of the present invention.
Claims (63)
1. A method of inhibiting the replication of HIV-1 virus, comprising the step of administering to a subject which is infected with HIV-1 a pharmaceutically effective amount of a composition which comprises lipos?mal vesicles in which a polyene selected from nystatin and amphotericin B is incorporated.
2. The method of claim 1, where the composition further comprises a sterol.
3. The method of claim 2, where the sterol is cholesterol.
4. The method of claim 2, where the sterol makes up between about 10% and about 75% by weight of the total amount of polyene, phospholipid, and sterol in the composition.
5. The method of claim 2, where the sterol makes up between about 30% and about 60% by weight of the total amount of polyene, phospholipid, and sterol in the composition.
6. The method of claim 1, where the mode of administration is parenteral.
7. The method of claim 1, where the composition comprises at least one phospholipid selected from phosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, sphingomyelin, and phosphatidic acid.
8. The method of claim 1, where the phospholipids in the composition consist essentially of dimyristoyl phosphatidyl choline and dimyristoyl phosphatidyl glycerol in a weight ratio of between about 1:10 and about 10:1.
9. The method of claim 8, where the ratio of DMPC
to DMPG is about 7:3.
to DMPG is about 7:3.
10. The method of claim 1, where the phospholipids make up between about 25% and about 90% by weight of the total amount of polyene and phospholipids.
11. A method of inhibiting the replication of HIV-1 virus, comprising the step of administering to a subject which is infected with HIV-1 a pharmaceutically effective amount of a composition which comprises liposomal vesicles in which nystatin is incorporated.
12. The method of claim 11, where the composition further comprises a sterol.
13. The method of claim 12, where the sterol is cholesterol.
14. The method of claim 12, where the sterol makes up between about 10% and about 75% by weight of the total amount of nystatin, phospholipid, and sterol in the composition.
15. The method of claim 12, where the sterol makes up between about 30% and about 60% by weight of the total amount of nystatin, phospholipid, and sterol in the composition.
16. The method of claim 11, where the mode of administration is parenteral.
17. The method of claim 11, where the composition comprises at least one phospholipid selected from phosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, sphingomyelin, and phosphatidic acid.
18. The method of claim 11, where the phospholipids in the composition consist essentially of dimyristoyl phosphatidyl choline and dimyristoyl phosphatidyl glycerol in a weight ratio of between about 1:10 and about 10:1.
19. The method of claim 18, where the ratio of DMPC
to DMPG is about 7:3.
to DMPG is about 7:3.
20. The method of claim 11, where the phospholipids make up between about 25% and about 90% by weight of the total amount of nystatin and phospholipids.
21. A method of inhibiting the replication of HIV-1 virus, comprising the step of administering to a subject which is infected with HIV-1 a pharmaceutically effective amount of a composition which comprises nystatin incorporated in liposomes, where the liposomes comprise phospholipids which consist essentially of dimyristoyl phosphatidyl glycerol and dimyristoyl phosphatidyl choline.
22. The method of claim 21, where the ratio of DMPC
to DMPG is about 7:3 by weight.
to DMPG is about 7:3 by weight.
23. The method of claim 21, where the composition further comprises cholesterol.
24. The method of claim 23, where cholesterol makes up between about 30% and about 60% of the total amount of nystatin, phospholipid, and cholesterol in the composition.
25. The method of claim 21, where the phospholipids make up between about 25% to about 90% by weight of the total amount of phospholipid and nystatin.
26. The method of claim 21, where the composition is administered to the subject in a dosage of about 4 mg nystatin per kg of body weight.
27. A method of inhibiting the replication of HIV-1 virus, comprising the step of parenterally administering to a subject which is infected with HIV-1 a pharmaceutically effective amount of a composition which comprises liposomal vesicles in which nystatin is incorporated, where the vesicles consist essentially of dimyristoyl phosphatidyl choline and dimyristoyl phosphatidyl glycerol in a weight ratio of about 7:3, and where the weight ratio of lipids to nystatin is about 10:1.
28. A cytotoxicity-exclusionary pharmaceutical composition comprising a cytotoxicity-exclusionary amount of a liposomal polyene selected from nystatin and amphotericin B.
29. The composition of claim 28 where the composition further comprises a sterol.
30. The composition of claim 29, where the sterol is cholesterol.
31. The composition of claim 29, where the sterol makes up between about 10% and about 75% by weight of the total amount of polyene, phospholipid, and sterol in the composition.
32. The composition of claim 29, where the sterol makes up between about 30% and about 60% by weight of the total amount of polyene, phospholipid, and sterol in the composition.
33. The composition of claim 28, where the composition comprises at least one phospholipid selected from phosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, sphingomyelin, and phosphatidic acid.
34. The composition of claim 33, where the phospholipids in the composition consist essentially of dimyristoyl phosphatidyl choline and dimyristoyl phosphatidyl glycerol in a weight ratio of between about 1:10 and about 10:1.
35. The composition of claim 34, where the ratio of DMPC to DMPG is about 7:3.
36. The composition of claim 28, where the phospholipids make up between about 25% and about 90% by weight of the total amount of polyene and phospholipids.
37. A method for treatment of an HIV-infected animal, comprising administering to the animal a cytotoxicity-exclusionary pharmaceutical composition comprising a liposomal polyene selected from nystatin and amphotericin B.
38. The method of claim 37, where the cytotoxicity-exclusionary composition is administered in an HIV vector-interdicting dosage.
39. A method of inhibiting the replication of HIV-1 virus, comprising the step of administering to a subject which is infected with HIV-1 a vector-interdicting amount of a composition which comprises liposomal vesicles in which a polyene selected from nystatin and amphotericin B
is incorporated.
is incorporated.
40. The method of claim 39, where the composition further comprises a sterol.
41. The method of claim 40, where the sterol is cholesterol.
42. The method of claim 40, where the sterol makes up between about 10% and about 75% by weight of the total amount of polyene, phospholipid, and sterol in the composition.
43. The method of claim 40, where the sterol makes up between about 30% and about 60% by weight of the total amount of polyene, phospholipid, and sterol in the composition.
44. The method of claim 39, where the mode of administration is parenteral.
45. The method of claim 39, where the composition comprises at least one phospholipid selected from phosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, sphingomyelin, and phosphatidic acid.
46. The method of claim 39, where the phospholipids in the composition consist essentially of dimyristoyl phosphatidyl choline and dimyristoyl phosphatidyl glycerol in a weight ratio of between about 1:10 and about 10:1.
47. The method of claim 46, where the ratio of DMPC
to DMPG is about 7:3.
to DMPG is about 7:3.
48. The method of claim 39, where the phospholipids make up between about 25% and about 90% by weight of the total amount of polyene and phospholipids.
Additional Claims 49 - 63
Additional Claims 49 - 63
49. A composition for use in a method for in vivo treatment of HIV-1 infections in a living subject, said composition comprising liposomes in which a polyene selected from nystatin and amphotericin B is incorporated.
50. The composition of claim 49, wherein said polyene is nystatin.
51. The composition of claim 49 or 50, wherein said liposomes comprise phospholipids which consist essentially of dimyristoyl phosphatidyl glycerol (DMPG) and dimyristoyl phosphatidyl choline (DMPC).
52. The composition of any of claims 49 - 51 being a cytotoxicity-exclusionary pharmaceutical composition.
53. The composition of any of claims 49 - 52, wherein said liposomes are contained in a vector-interdicting dosage.
54. The composition of any of the preceding claims, wherein said treat-ment comprises parenteral administration.
55. The composition of any of the preceding claims comprising a dosage of about 4 mg polyene per kg of body weight.
56. The composition of any of the preceding claims, further comprising a sterol.
57. The composition of claim 56, wherein the sterol is cholesterol.
58. The composition of claim 56, wherein the sterol makes up between about 10% and about 75% by weight of the total amount of poly-ene, phospholipid, and sterol in the composition.
59. The composition of claim 56, wherein the sterol makes up between about 30% and about 60% by weight of the total amount of poly-ene, phospholipid, and sterol in the composition.
60. The composition of any of the preceding claims, wherein the compo-sition comprises at least one phospholipid selected from phosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, sphingomyelin, and phosphatidic acid.
61. The composition of any of the preceding claims, wherein the phospholipids in the composition consist essentially of dimyristoyl phosphatidyl choline (DMPC) and dimyristoyl phosphatidyl glycerol (DMPG) in a weight ratio of between about 1:10 and about 10:1.
62. The composition of claim 61, wherein the ratio of DMPC to DMPG
is about 7:3.
is about 7:3.
63. The composition of any of the preceding claims, wherein the phospholipids make up between about 25% and about 90% by weight of the total amount of polyene and phospholipids.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64069491A | 1991-01-14 | 1991-01-14 | |
| US640,694 | 1991-01-14 | ||
| PCT/US1992/000057 WO1992011841A1 (en) | 1991-01-14 | 1992-01-03 | Anti-hiv activity of liposomal nystatin and amphotericin b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2099772A1 true CA2099772A1 (en) | 1992-07-15 |
Family
ID=24569326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002099772A Abandoned CA2099772A1 (en) | 1991-01-14 | 1992-01-03 | Anti-hiv activity of liposomal nystatin and amphotericin b |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0567559A1 (en) |
| JP (1) | JPH06509058A (en) |
| AU (1) | AU1201192A (en) |
| CA (1) | CA2099772A1 (en) |
| WO (1) | WO1992011841A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070053918A1 (en) * | 2003-05-12 | 2007-03-08 | Novosom Ag | Injectable depots consisting of liposomal aggregates for the delivery of active substances |
| EP4322963A1 (en) * | 2021-04-16 | 2024-02-21 | Pannonpharma Gyógyszergyártó Kft. | Treatment for viral infection with polyene macrolide antibiotic |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE60901B1 (en) * | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US4812312A (en) * | 1987-03-03 | 1989-03-14 | Board Of Regents Of The University Of Texas System | Liposome-incorporated nystatin |
| AU598958B2 (en) * | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
| US5032404A (en) * | 1989-02-23 | 1991-07-16 | Board Of Regents, The University Of Texas System | Lipsome-incorporation of polyenes |
-
1992
- 1992-01-03 JP JP4504447A patent/JPH06509058A/en active Pending
- 1992-01-03 CA CA002099772A patent/CA2099772A1/en not_active Abandoned
- 1992-01-03 EP EP92904286A patent/EP0567559A1/en not_active Withdrawn
- 1992-01-03 AU AU12011/92A patent/AU1201192A/en not_active Abandoned
- 1992-01-03 WO PCT/US1992/000057 patent/WO1992011841A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992011841A1 (en) | 1992-07-23 |
| AU1201192A (en) | 1992-08-17 |
| JPH06509058A (en) | 1994-10-13 |
| EP0567559A1 (en) | 1993-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Magnani et al. | Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. | |
| JP2825804B2 (en) | Liposomes with antigen introduced | |
| EP0296212A1 (en) | Liposomes with enhanced circulation time. | |
| JPH02501576A (en) | Novel antiretroviral agents and delivery systems | |
| Koldin et al. | Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits | |
| JPH06501680A (en) | Autobiotics and their use to eliminate non-self cells in vivo | |
| Machy et al. | Freezing of liposomes | |
| WO2004052294A2 (en) | Compositions and methods related to lipid:emodin formulations | |
| Désormeaux et al. | Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2', 3'-dideoxyinosine | |
| CA2099772A1 (en) | Anti-hiv activity of liposomal nystatin and amphotericin b | |
| EP0552280B1 (en) | Inhibition of viral replication | |
| EP0183352A2 (en) | Use of suramin for clinical treatment of infection with any of the members of the family of human-t-cell leukemia (htvl) viruses including lymphadenopathy virus (lav) | |
| Szoka Jr et al. | Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes | |
| US20120207821A1 (en) | Liposomal formulation and use thereof | |
| EA001957B1 (en) | Composition for aids treatment | |
| Crews et al. | Lipids are major components of human immunodeficiency virus (HIV): Modification of HIV lipid composition, membrane organization, and protein conformation by AL‐721® | |
| Vertut-Croquin et al. | Transfer of amphotericin B from gel state vesicles to mycoplasma cells: biphasic action on potassium transport and permeability | |
| NO973666D0 (en) | Contrast-containing liposomes for imaging of the intravascular compartment | |
| RU2203071C2 (en) | Application of proteins as antiretroviral agents | |
| WO1989005152A1 (en) | Liposome-encapsulated anti-viral composition and method | |
| JPH0474116A (en) | Liposome | |
| Magnani et al. | Red blood cells as carriers of drugs against retroviruses | |
| Abbas et al. | Efficacy of Amphotericine B Ddrug Against Promastigote and Axenic Amastigote of Leishmania Dononvani in Vitro | |
| Tyring et al. | Ethanol, disulfiram, and pyrazole: Effects on interferon production in mice | |
| Zumbühl et al. | Cytotoxic effect of unilamellar detergent dialysis liposomes on Trypanosoma brucei and Trypanosoma congolense bloodstream forms in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 19960703 |